HC Wainwright Boosts Personalis (NASDAQ:PSNL) Price Target to $9.00

Personalis (NASDAQ:PSNL) had its price objective boosted by HC Wainwright from $7.50 to $9.00 in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.01) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.89) EPS.

A number of other brokerages have also recently commented on PSNL. Lake Street Capital began coverage on shares of Personalis in a research note on Tuesday, April 30th. They set a buy rating and a $4.00 price target for the company. BTIG Research raised their price target on shares of Personalis from $5.50 to $7.00 and gave the stock a buy rating in a research note on Friday, August 16th. Finally, Needham & Company LLC raised their price target on shares of Personalis from $5.50 to $7.25 and gave the stock a buy rating in a research note on Friday, August 16th.

Personalis Stock Up 11.4 %

PSNL stock opened at $6.34 on Monday. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20. The company has a market cap of $329.29 million, a PE ratio of -3.34 and a beta of 1.85. The business’s 50-day simple moving average is $2.63 and its 200 day simple moving average is $1.84.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The business had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same period last year, the business earned ($0.50) earnings per share. On average, equities research analysts anticipate that Personalis will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in shares of Personalis in the first quarter valued at approximately $29,000. GSA Capital Partners LLP raised its stake in shares of Personalis by 6.2% in the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock valued at $626,000 after acquiring an additional 24,498 shares during the last quarter. Virtu Financial LLC bought a new position in Personalis in the 1st quarter worth approximately $41,000. Price T Rowe Associates Inc. MD raised its position in Personalis by 58.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock worth $142,000 after purchasing an additional 34,900 shares during the last quarter. Finally, State of Michigan Retirement System raised its position in Personalis by 11.3% in the 1st quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.